Brokerages Set Zealand Pharma (ZEAL) Target Price at $27.33

Shares of Zealand Pharma (NASDAQ:ZEAL) have earned an average rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $27.33.

Several research firms have issued reports on ZEAL. Zacks Investment Research lowered shares of Zealand Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. ValuEngine upgraded shares of Zealand Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Get Zealand Pharma alerts:

Hedge funds and other institutional investors have recently bought and sold shares of the business. OLD Mission Capital LLC purchased a new position in Zealand Pharma during the 4th quarter worth approximately $215,000. Fred Alger Management Inc. purchased a new position in Zealand Pharma during the 4th quarter worth approximately $544,000. Finally, AWM Investment Company Inc. grew its position in Zealand Pharma by 8.1% during the 4th quarter. AWM Investment Company Inc. now owns 302,901 shares of the company’s stock worth $4,119,000 after purchasing an additional 22,700 shares in the last quarter. Hedge funds and other institutional investors own 9.07% of the company’s stock.

Zealand Pharma stock traded up $0.17 during mid-day trading on Wednesday, hitting $15.39. The company’s stock had a trading volume of 4,904 shares, compared to its average volume of 19,552. The firm has a market cap of $468.04 million and a price-to-earnings ratio of -10.54. Zealand Pharma has a twelve month low of $12.45 and a twelve month high of $20.37.

Zealand Pharma (NASDAQ:ZEAL) last posted its quarterly earnings results on Wednesday, March 7th. The company reported ($0.58) earnings per share (EPS) for the quarter. The business had revenue of $1.78 million during the quarter. Zealand Pharma had a negative return on equity of 68.26% and a negative net margin of 200.15%.

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Leave a Reply

Your email address will not be published. Required fields are marked *